According to a recent LinkedIn post from Cooler Heads, the company is drawing attention to a new Category I CPT coding update that applies specifically to FDA-cleared mechanical scalp cooling systems when services are delivered by qualified healthcare providers. The post highlights that Cooler Heads’ Amma device uses FDA-cleared technology, positioning it to fit within the scope of these coding changes and potential reimbursement pathways.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that this reimbursement-oriented development could improve economic feasibility for providers offering scalp cooling and may lower financial barriers for eligible adult cancer patients. For investors, clearer CPT guidance and alignment with FDA-cleared status may support broader clinical adoption of Amma, potentially strengthening Cooler Heads’ revenue prospects and competitive standing in the scalp cooling and oncology-support market.

